Anti-MMP9 Antibody (such as Andecaliximab/GS-5745) is a highly specific neutralizing antibody against Matrix Metalloproteinase-9 (MMP9). By inhibiting the enzymatic activity of MMP9, it effectively prevents extracellular matrix degradation, thereby suppressing tumor invasion, metastasis, and angiogenesis, and has research value in gastrointestinal tumors and inflammatory diseases such as Crohn's disease.